美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

CAR-T

1,574.04

-5.9235-0.37%

涨家数：- -

跌家数：2

平家数：- -

市盈率：- -

高：1,586.77

开：1,579.01

低：1,565.30

收：1,579.97

成交量：842.20万

成交额：10.61亿

市值：4,092.10亿

流通市值：3,968.23亿

数据加载中...

总览新闻资讯

吉利德科学的单片剂方案在III期ARTISTRY-1试验中达到主要终点

港股异动 | 中国同辐(01763)再涨超8% 诺华核药在华获批上市有望点燃国内核医学行业热度

吉利德科学首席财务官表示公司将继续积极开展业务发展，包括许可和并购

吉利德科学首席财务官表示医保改革对艾滋病业务影响约为9亿美元，整体业务影响达12亿美元

背景资料-过去十年涉及美国制药商和生物技术公司的重大交易

VR互动解锁创新！诺华心肾药加速惠及中国患者

进博首日旗下核药获批上市诺华迎来开门红

国际金融报

吉利德：Trop2 ADC一线治疗HR+/HER2-乳腺三期临床失败

吉利德：预计2024年第四季度可享受4.5亿美元的所得税优惠，同时减少对应的5.3亿美元未确认税收优惠

吉利德科学：10月与税务机关达成与前一年法律实体重组相关的和解 - 文件

吉利德科学股价下跌2.2%，乳腺癌药物未达晚期研究主要目标

吉利德乳腺癌药物未能达到后期研究的主要目标

吉利德：安全性特征与之前Trodelvy乳腺癌研究一致，未在该患者群体中发现新的安全性信号

吉利德：Livdelzi独家新数据凸显其作为PBC患者有效且耐受良好选择的潜力

吉利德的Livdelzi®在原发性胆汁性胆管炎（PBC）中显示持续疗效，提供碱性磷酸酶（Alp）降低、缓解瘙痒及减缓疾病进展的潜力

吉利德科学携两款亚洲首发展品亮相进博会

西门子医疗中国与诺华公司签署战略合作备忘录

由于生产成本降低和研发削减，莫德纳下调了年度支出展望

由于 COVID 疫苗销售疲软，莫德纳下调了全年预期上限

诺华制药(NVS.US)首个放射配体疗法药物派威妥®双适应症同时获批

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK4578/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4578","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T","latestPrice":1574.044,"timestamp":1763153999999,"preClose":1579.9674,"halted":0,"volume":8421973,"delay":0,"changeRate":-0.003749,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":-5.923462,"latestTime":"11-14 16:00:00 EST","open":1579.0128,"high":1586.7693,"low":1565.2983,"amount":1061009430.451513,"amplitude":0.013589,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763389800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.198531,"peRate":18.144126,"turnoverRate":0.002733,"increases":0,"decrements":2,"flats":0,"marketCap":409209847808,"floatMarketCap":396823134208},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1586.7693,"amplitude":0.013589,"preClose":1579.9674,"low":1565.2983,"pbRate":"6.198531","latestPrice":1574.044,"volume":8421973,"delay":0,"open":1579.0128,"prevYearClose":1164.883,"prevWeekClose":1574.044,"prevMonthClose":1493.5356,"prevQuarterClose":1484.4005,"fiveDayClose":1508.2035,"twentyDayClose":1565.0261,"sixtyDayClose":1498.6538,"secType":"PLATE","market":"US","turnoverRate":0.002733,"peRate":18.144126,"marketCap":409209847808,"floatMarketCap":396823134208,"timestamp":1763153999999,"nameCN":"CAR-T"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":0,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1188771558","title":"吉利德科学的单片剂方案在III期ARTISTRY-1试验中达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1188771558","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188771558?lang=zh_cn&edition=fundamental","pubTime":"2025-11-13 21:31","pubTimestamp":1763040716,"startTime":"0","endTime":"0","summary":"吉利德科学的单片剂方案Bictegravir和Lenacapavir用于HIV-1治疗在III期ARTISTRY-1试验中达到了主要终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","IE00B19Z3581.USD","LU1585245621.USD","BK4583","LU1839511570.USD","BK4588","LU1571399168.USD","BK4585","IE00BZ1G4Q59.USD","SG9999015986.USD","GILD","LU1674673691.USD","BK4568","IE00B19Z3B42.SGD","LU0289739699.SGD","IE00BKVL7J92.USD","LU0889565916.HKD","LU1674673428.USD","BK4139","LU0882574055.USD","LU0109394709.USD","LU2468319806.SGD","LU1066051498.USD","BK4550","IE00B7SZLL34.SGD","LU0320765992.SGD","LU2087621335.USD","BK4532","LU0823416689.USD","LU1430594728.SGD","IE00BSNM7G36.USD","SG9999015978.USD","IE0002270589.USD","BK4566","LU0234570918.USD","LU1778281490.HKD","IE00B3T34201.USD","LU2089984988.USD","LU1066053197.SGD","BK4578","LU0114720955.EUR","LU2324357040.USD","SG9999015952.SGD","SG9999015945.SGD"],"gpt_icon":0},{"id":"2582310965","title":"港股异动 | 中国同辐(01763)再涨超8% 诺华核药在华获批上市 有望点燃国内核医学行业热度","url":"https://stock-news.laohu8.com/highlight/detail?id=2582310965","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582310965?lang=zh_cn&edition=fundamental","pubTime":"2025-11-12 10:55","pubTimestamp":1762916116,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国同辐再涨超8%，年内股价累涨逾130%。截至发稿，涨7.94%，报24.48港元，成交额1302.97万港元。消息面上，11月5日，诺华宣布其放射配体疗法药物Pluvicto的两个适应症同时获得国家药监局批准。据悉，Pluvicto为诺华旗下的一款核药爆品。平安证券指出，Pluvicto的获批有望进一步点燃国内核医学行业热度，AD诊断核药有望随着治疗药物一同放量，建议关注国内在新核素和新靶点方面布局领先的企业，比如中国同辐等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0211331839.USD","IE00BJJMRZ35.SGD","BK4007","01763","IE00B4R5TH58.HKD","LU0320765489.SGD","IE0009355771.USD","BK4578","LU0070302665.USD","BK4532","BK4588","IE0002141913.USD","BK4585","NVS","BK1222","LU0208291251.USD"],"gpt_icon":0},{"id":"1157913444","title":"吉利德科学首席财务官表示公司将继续积极开展业务发展，包括许可和并购","url":"https://stock-news.laohu8.com/highlight/detail?id=1157913444","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157913444?lang=zh_cn&edition=fundamental","pubTime":"2025-11-11 00:35","pubTimestamp":1762792519,"startTime":"0","endTime":"0","summary":"吉利德科学首席财务官表示公司将继续积极开展业务发展，包括许可和并购。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU1674673428.USD","BK4550","BK4578","IE00B19Z3B42.SGD","LU0320765992.SGD","LU2468319806.SGD","LU1778281490.HKD","LU0109394709.USD","BK4532","LU1066053197.SGD","SG9999015986.USD","BK4568","IE00BZ1G4Q59.USD","LU1674673691.USD","LU1571399168.USD","IE00BKVL7J92.USD","LU0114720955.EUR","LU0882574055.USD","LU1430594728.SGD","SG9999015945.SGD","LU0234570918.USD","BK4583","BK4588","GILD","LU0823416689.USD","LU0889565916.HKD","LU2087621335.USD","SG9999015952.SGD","IE00B3T34201.USD","IE0002270589.USD","BK4139","IE00B7SZLL34.SGD","LU2089984988.USD","BK4566","SG9999015978.USD","BK4585","LU1585245621.USD","LU2324357040.USD","LU1066051498.USD","IE00BSNM7G36.USD","LU1839511570.USD","LU0289739699.SGD","LU0058720904.USD"],"gpt_icon":0},{"id":"1145102354","title":"吉利德科学首席财务官表示医保改革对艾滋病业务影响约为9亿美元，整体业务影响达12亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1145102354","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145102354?lang=zh_cn&edition=fundamental","pubTime":"2025-11-11 00:13","pubTimestamp":1762791201,"startTime":"0","endTime":"0","summary":"吉利德科学首席财务官表示，医保改革对艾滋病业务的影响约为9亿美元，整体业务的影响则达到12亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B7SZLL34.SGD","IE0002270589.USD","LU2087621335.USD","LU2089984988.USD","BK4532","LU1674673428.USD","LU1674673691.USD","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","BK4585","LU0889565916.HKD","LU1430594728.SGD","IE00BZ1G4Q59.USD","LU1066051498.USD","SG9999015952.SGD","LU0114720955.EUR","LU1778281490.HKD","IE00BKVL7J92.USD","IE00B3T34201.USD","LU2468319806.SGD","LU1066053197.SGD","SG9999015945.SGD","LU1585245621.USD","LU0109394709.USD","LU2324357040.USD","BK4578","LU0882574055.USD","BK4566","SG9999015986.USD","LU0058720904.USD","BK4583","BK4568","LU0320765992.SGD","IE00B19Z3581.USD","BK4139","BK4550","LU0234570918.USD","LU0289739699.SGD","LU0823416689.USD","LU1571399168.USD","GILD","LU1839511570.USD","SG9999015978.USD"],"gpt_icon":0},{"id":"2582820431","title":"背景资料-过去十年涉及美国制药商和生物技术公司的重大交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2582820431","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582820431?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 19:23","pubTimestamp":1762773795,"startTime":"0","endTime":"0","summary":"在过去十年中，美国制药公司为收购从肿瘤学、神经学到罕见病和肥胖症等领域前景看好的疗法而进行的引人注目的交易越来越多，此举为这一交易添上了浓墨重彩的一笔。根据LSEG编制的数据，截至今年7月9日，全球已签署了价值1053亿美元的制药和生物技术并购交易，比去年同期增长了7%，创下了自2023年以来的最高纪录。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL4T3WM0SQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2361044949.HKD","LU0792757196.USD","MTSR","LU0203347892.USD","LU0310800379.SGD","LU0708994859.HKD","LU2237443465.HKD","IE00B7SZLL34.SGD","IE0002141913.USD","LU2324357040.USD","MRK","IE00B4R5TH58.HKD","LU0985320562.USD","LU1267930573.SGD","LU1670710661.SGD","LU1929549753.HKD","IE00B42XCP33.USD","LU1670711123.USD","LU1941712264.USD","IE000M9KFDE8.USD","LU2471134952.CNY","LU1059921491.USD","LU1196500208.SGD","LU1732800096.USD","LU2237443622.USD","BK4578","LU1868836757.USD","LU1699723380.USD","LU2468319806.SGD","IE0034235303.USD","GILD","JNJ","IE00BGHQF631.EUR","LU2361044865.SGD","LU2237443549.SGD","IE00B3PB1722.GBP","BMY","LU2237443382.USD","LU1061106388.HKD","LU1057294990.SGD","SG9999013999.USD","VTRS","IE00BKVL7J92.USD","LU2089283258.USD","LU1023059063.AUD","PFE","LU2361045086.USD","LU1670710588.SGD","BK4516","ABBV"],"gpt_icon":1},{"id":"2582789911","title":"VR互动解锁创新！诺华心肾药加速惠及中国患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2582789911","media":"上观新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582789911?lang=zh_cn&edition=fundamental","pubTime":"2025-11-09 16:58","pubTimestamp":1762678709,"startTime":"0","endTime":"0","summary":"诺华公司今年进博会期间集中展示多款突破性创新药物与前沿治疗方案，涵盖从高血压、高血脂及IgA肾病（IgAN）等重大疾病领域。在展示形式上，针对获批后再次亮相进博会的肾科产品组合，采用了创新性虚拟现实的交互方式，可通过手势、视线或触控与虚拟内容互动，更直观地了解常见肾脏疾病的发病机制、诊断方法以及沉浸式体验药物在肾脏内的作用机制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511093559016533.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["NVS","BK4007","IE00BJT1NW94.SGD","BK4532","BK4588","IE0002141913.USD","IE00B2B36J28.USD","BK4578","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0320765489.SGD","VR","LU0070302665.USD","LU0208291251.USD","IE00B4R5TH58.HKD","LU0211331839.USD","BK4585"],"gpt_icon":0},{"id":"2581859013","title":"进博首日旗下核药获批上市 诺华迎来开门红","url":"https://stock-news.laohu8.com/highlight/detail?id=2581859013","media":"国际金融报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581859013?lang=zh_cn&edition=fundamental","pubTime":"2025-11-08 13:32","pubTimestamp":1762579961,"startTime":"0","endTime":"0","summary":"11月7日，记者从瑞士制药巨头诺华公司获悉，在第八届进博会开幕首日，该公司首个放射配体疗法药物（RLT）镥[177Lu]特昔维匹肽注射液（商品名：派威妥）双适应症同时获得国家药监局批准上市，这也是国内首个获批的靶向前列腺特异性膜抗原的放射配体疗法药物，为中国晚期前列腺患者带来新的治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511083558860536.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511083558860536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4532","BK4588","IE00B2B36J28.USD","LU0320765489.SGD","IE00B4R5TH58.HKD","IE0002141913.USD","NVS","IE00BJJMRZ35.SGD","IE0009355771.USD","LU0070302665.USD","BK4007","IE00BJT1NW94.SGD","LU0208291251.USD","LU0211331839.USD","BK4578","IE00BFTCPJ56.SGD","BK4585"],"gpt_icon":0},{"id":"2582862418","title":"吉利德：Trop2 ADC一线治疗HR+/HER2-乳腺三期临床失败","url":"https://stock-news.laohu8.com/highlight/detail?id=2582862418","media":"医药笔记","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582862418?lang=zh_cn&edition=fundamental","pubTime":"2025-11-08 09:31","pubTimestamp":1762565499,"startTime":"0","endTime":"0","summary":"▎Armstrong2025年11月7日，吉利德宣布Trop2 ADC新药Trodelvy对比化疗一线治疗内分泌治疗后HR+/HER2-乳腺癌的三期临床ASCENT-07没有达到PFS主要终点，关键次要终点OS尚未成熟，但观察到获益趋势，研究将继续进行以评估OS数据。Trodelvy一线治疗三阴乳腺癌已经递交上市申请。总结吉利德Trodelvy为全球首款Trop2 ADC，但作为上一代ADC在适应症拓展的道路上充满曲折，先后在非小细胞肺癌、尿路上皮癌失败，此次HR+/HER2-乳腺癌又错失PFS终点，仅守住三阴乳腺癌这一阵地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108093356a6e9fd53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108093356a6e9fd53&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","BK4550","BK4585","BK4231","IE00BSNM7G36.USD","LU1066053197.SGD","ADC","LU0289739699.SGD","LU0058720904.USD","LU0823416689.USD","GILD","IE00B19Z3581.USD","BK4080","LU1066051498.USD","LU2324357040.USD","BK4583","LU0234570918.USD","LU0114720955.EUR","IE00B19Z3B42.SGD","SG9999015986.USD","SG9999015945.SGD","SG9999015978.USD","LU0320765992.SGD","BK4578","LU1585245621.USD","BK4588","HR","LU2087621335.USD","LU0109394709.USD","BK4139","IE00B7SZLL34.SGD","LU1839511570.USD","BK4225","IE00BKVL7J92.USD","BK4532","BK4203","LU1674673691.USD","LU2089984988.USD","BK4566","BK4568","LU1778281490.HKD","LU1430594728.SGD","LU0882574055.USD","LU2468319806.SGD","IE0002270589.USD","IE00B3T34201.USD","SG9999015952.SGD","LU1571399168.USD","IE00BZ1G4Q59.USD","LU1674673428.USD"],"gpt_icon":0},{"id":"1152764069","title":"吉利德：预计2024年第四季度可享受4.5亿美元的所得税优惠，同时减少对应的5.3亿美元未确认税收优惠","url":"https://stock-news.laohu8.com/highlight/detail?id=1152764069","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152764069?lang=zh_cn&edition=fundamental","pubTime":"2025-11-08 05:13","pubTimestamp":1762549994,"startTime":"0","endTime":"0","summary":"吉利德：预计2024年第四季度可享受4.5亿美元的所得税优惠，同时减少对应的5.3亿美元未确认税收优惠。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BSNM7G36.USD","LU2468319806.SGD","LU0889565916.HKD","LU1674673691.USD","BK4568","BK4578","BK4588","LU1066051498.USD","IE00B3T34201.USD","SG9999015986.USD","LU2087621335.USD","BK4566","GILD","LU1839511570.USD","LU1066053197.SGD","LU1430594728.SGD","LU0320765992.SGD","BK4139","BK4532","LU1674673428.USD","LU0882574055.USD","IE00B7SZLL34.SGD","BK4585","LU2324357040.USD","SG9999015978.USD","SG9999015945.SGD","LU0823416689.USD","IE0002270589.USD","SG9999015952.SGD","BK4550","LU0289739699.SGD","LU1571399168.USD","LU0058720904.USD","LU1778281490.HKD","IE00BZ1G4Q59.USD","LU0109394709.USD","LU0234570918.USD","BK4583","LU2089984988.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","IE00BKVL7J92.USD","LU0114720955.EUR","LU1585245621.USD"],"gpt_icon":0},{"id":"1184501887","title":"吉利德科学：10月与税务机关达成与前一年法律实体重组相关的和解 - 文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1184501887","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184501887?lang=zh_cn&edition=fundamental","pubTime":"2025-11-08 05:13","pubTimestamp":1762549993,"startTime":"0","endTime":"0","summary":"吉利德科学：10月与税务机关达成与前一年法律实体重组相关的和解 - 文件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1839511570.USD","SG9999015978.USD","BK4585","IE00B19Z3B42.SGD","LU0234570918.USD","LU0289739699.SGD","BK4550","SG9999015986.USD","LU1430594728.SGD","LU2087621335.USD","IE00BZ1G4Q59.USD","BK4532","LU0882574055.USD","LU2324357040.USD","LU1674673691.USD","LU1778281490.HKD","LU0889565916.HKD","IE00B19Z3581.USD","IE00B7SZLL34.SGD","LU0109394709.USD","LU1066051498.USD","IE00BSNM7G36.USD","BK4583","SG9999015945.SGD","BK4578","LU1571399168.USD","LU2089984988.USD","LU1674673428.USD","BK4568","LU0114720955.EUR","LU0058720904.USD","LU0320765992.SGD","SG9999015952.SGD","GILD","IE00BKVL7J92.USD","LU1585245621.USD","LU2468319806.SGD","BK4139","LU1066053197.SGD","IE00B3T34201.USD","BK4566","IE0002270589.USD","LU0823416689.USD","BK4588"],"gpt_icon":0},{"id":"1157980952","title":"吉利德科学股价下跌2.2%，乳腺癌药物未达晚期研究主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1157980952","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157980952?lang=zh_cn&edition=fundamental","pubTime":"2025-11-07 22:59","pubTimestamp":1762527560,"startTime":"0","endTime":"0","summary":"吉利德科学股价下跌2.2%，乳腺癌药物未达晚期研究主要目标","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","LU1571399168.USD","LU1778281490.HKD","IE00B3T34201.USD","BK4532","BK4578","LU2087621335.USD","SG9999015978.USD","LU1674673691.USD","IE00B19Z3B42.SGD","LU2089984988.USD","IE00B19Z3581.USD","SG9999015952.SGD","GILD","LU0234570918.USD","LU0320765992.SGD","LU1839511570.USD","SG9999015986.USD","LU0882574055.USD","LU1585245621.USD","LU1066051498.USD","IE00BKVL7J92.USD","IE00BSNM7G36.USD","BK4568","IE00BZ1G4Q59.USD","BK4583","LU0889565916.HKD","BK4585","SG9999015945.SGD","LU1066053197.SGD","LU0058720904.USD","IE00B7SZLL34.SGD","LU0114720955.EUR","LU2324357040.USD","BK4588","LU1430594728.SGD","IE0002270589.USD","BK4139","LU0289739699.SGD","BK4550","LU0109394709.USD","LU0823416689.USD","LU1674673428.USD","BK4566"],"gpt_icon":0},{"id":"2581885593","title":"吉利德乳腺癌药物未能达到后期研究的主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2581885593","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581885593?lang=zh_cn&edition=fundamental","pubTime":"2025-11-07 21:37","pubTimestamp":1762522627,"startTime":"0","endTime":"0","summary":"吉利德乳腺癌药物未能达到后期研究的主要目标路透11月7日 - 吉利德科学公司GILD.O周五称，其乳腺癌药物Trodelvy未能达到一项晚期研究的主要目标。 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL4T3WJ164:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU1585245621.USD","LU2324357040.USD","LU1571399168.USD","BK4578","SG9999015952.SGD","BK4583","IE00B7SZLL34.SGD","IE00BKVL7J92.USD","SG9999015986.USD","LU1674673428.USD","BK4588","LU0058720904.USD","LU1778281490.HKD","LU0234570918.USD","LU1839511570.USD","LU0289739699.SGD","LU0882574055.USD","SG9999015945.SGD","BK4585","LU2089984988.USD","LU1066051498.USD","IE00B3T34201.USD","LU0109394709.USD","BK4550","LU1066053197.SGD","LU2468319806.SGD","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","SG9999015978.USD","LU2087621335.USD","LU0320765992.SGD","LU0823416689.USD","BK4566","IE00B19Z3581.USD","IE00BZ1G4Q59.USD","BK4568","LU1430594728.SGD","BK4139","LU1674673691.USD","LU0114720955.EUR","IE0002270589.USD","BK4532","GILD"],"gpt_icon":0},{"id":"1160960792","title":"吉利德：安全性特征与之前Trodelvy乳腺癌研究一致，未在该患者群体中发现新的安全性信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1160960792","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160960792?lang=zh_cn&edition=fundamental","pubTime":"2025-11-07 21:31","pubTimestamp":1762522292,"startTime":"0","endTime":"0","summary":"吉利德：安全性特征与之前Trodelvy乳腺癌研究一致，未在该患者群体中发现新的安全性信号","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0882574055.USD","LU0114720955.EUR","LU1066053197.SGD","LU2089984988.USD","SG9999015978.USD","LU0234570918.USD","LU0320765992.SGD","LU1585245621.USD","SG9999015945.SGD","BK4568","LU0289739699.SGD","LU2087621335.USD","LU0109394709.USD","BK4583","IE0002270589.USD","IE00BKVL7J92.USD","LU2324357040.USD","LU1674673691.USD","BK4550","LU1571399168.USD","BK4566","LU1066051498.USD","IE00BZ1G4Q59.USD","LU0058720904.USD","LU1430594728.SGD","LU2468319806.SGD","LU1839511570.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","IE00B7SZLL34.SGD","BK4532","LU0823416689.USD","BK4139","BK4578","LU1778281490.HKD","LU1674673428.USD","BK4585","SG9999015986.USD","GILD","LU0889565916.HKD","SG9999015952.SGD","IE00B3T34201.USD"],"gpt_icon":0},{"id":"1115807732","title":"吉利德：Livdelzi独家新数据凸显其作为PBC患者有效且耐受良好选择的潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1115807732","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115807732?lang=zh_cn&edition=fundamental","pubTime":"2025-11-07 21:02","pubTimestamp":1762520536,"startTime":"0","endTime":"0","summary":"吉利德：Livdelzi独家新数据凸显其作为PBC患者有效且耐受良好选择的潜力","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4583","IE00BZ1G4Q59.USD","LU0889565916.HKD","LU0882574055.USD","LU1839511570.USD","LU2468319806.SGD","SG9999015952.SGD","LU0823416689.USD","BK4588","LU2087621335.USD","BK4578","SG9999015945.SGD","BK4568","LU2089984988.USD","IE00B19Z3581.USD","IE00B3T34201.USD","BK4532","LU0109394709.USD","LU1778281490.HKD","LU1674673691.USD","LU1066051498.USD","LU0234570918.USD","LU1066053197.SGD","GILD","BK4566","IE00BSNM7G36.USD","LU0320765992.SGD","LU1571399168.USD","BK4585","IE00BKVL7J92.USD","SG9999015986.USD","LU1430594728.SGD","IE0002270589.USD","LU0114720955.EUR","LU1674673428.USD","BK4550","LU0289739699.SGD","LU1585245621.USD","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","LU2324357040.USD","LU0058720904.USD","SG9999015978.USD"],"gpt_icon":0},{"id":"1188865722","title":"吉利德的Livdelzi®在原发性胆汁性胆管炎（PBC）中显示持续疗效，提供碱性磷酸酶（Alp）降低、缓解瘙痒及减缓疾病进展的潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1188865722","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188865722?lang=zh_cn&edition=fundamental","pubTime":"2025-11-07 21:01","pubTimestamp":1762520508,"startTime":"0","endTime":"0","summary":"吉利德的Livdelzi®在原发性胆汁性胆管炎（PBC）中显示出持续的疗效，能够降低碱性磷酸酶（Alp）水平，缓解瘙痒感，并有潜力减缓疾病的进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU0320765992.SGD","IE00BSNM7G36.USD","LU1066051498.USD","SG9999015986.USD","BK4532","BK4588","LU1674673691.USD","BK4139","LU0058720904.USD","IE00BKVL7J92.USD","LU2468319806.SGD","IE00B3T34201.USD","BK4550","LU1571399168.USD","BK4585","LU2087621335.USD","LU0109394709.USD","LU1839511570.USD","LU1674673428.USD","GILD","SG9999015952.SGD","LU1778281490.HKD","BK4583","LU0289739699.SGD","SG9999015945.SGD","IE0002270589.USD","IE00B19Z3581.USD","LU0234570918.USD","LU2324357040.USD","BK4578","BK4568","IE00B19Z3B42.SGD","LU0889565916.HKD","SG9999015978.USD","LU1585245621.USD","LU0882574055.USD","LU2089984988.USD","LU0823416689.USD","LU1066053197.SGD","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","LU1430594728.SGD","LU0114720955.EUR"],"gpt_icon":0},{"id":"2581079810","title":"吉利德科学携两款亚洲首发展品亮相进博会","url":"https://stock-news.laohu8.com/highlight/detail?id=2581079810","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581079810?lang=zh_cn&edition=fundamental","pubTime":"2025-11-07 19:59","pubTimestamp":1762516799,"startTime":"0","endTime":"0","summary":"在第八届中国国际进口博览会（以下简称进博会）上，吉利德科学携多款产品亮相，其中包括两款亚洲首发产品：长效HIV暴露前预防药物Lenacapavir（来那帕韦）和原发性胆汁性胆管炎（PBC）新药Seladelpar，以及在华上市的13款创新药物等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511073558461893.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511073558461893.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1674673691.USD","LU1839511570.USD","BK4588","LU1571399168.USD","IE00B19Z3B42.SGD","SG9999015986.USD","BK4568","SG9999015945.SGD","LU0109394709.USD","LU0234570918.USD","LU0114720955.EUR","IE00B7SZLL34.SGD","BK4139","IE00BSNM7G36.USD","BK4566","BK4578","IE00B3T34201.USD","LU0320765992.SGD","LU1066051498.USD","BK4550","LU1585245621.USD","LU2468319806.SGD","IE00BZ1G4Q59.USD","SG9999015978.USD","IE00B19Z3581.USD","LU1066053197.SGD","BK4585","LU0889565916.HKD","LU2324357040.USD","LU2089984988.USD","BK4532","LU1674673428.USD","BK4583","LU1778281490.HKD","GILD","IE0002270589.USD","IE00BKVL7J92.USD","LU0289739699.SGD","LU0882574055.USD","SG9999015952.SGD","LU2087621335.USD","LU0058720904.USD","LU1430594728.SGD","LU0823416689.USD"],"gpt_icon":0},{"id":"2581331988","title":"西门子医疗中国与诺华公司签署战略合作备忘录","url":"https://stock-news.laohu8.com/highlight/detail?id=2581331988","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581331988?lang=zh_cn&edition=fundamental","pubTime":"2025-11-07 19:30","pubTimestamp":1762515000,"startTime":"0","endTime":"0","summary":"2025年6月，西门子医疗分子影像业务与美国麻省总医院宣布将合作新建治疗指挥中心。此次与诺华公司的战略合作，是西门子医疗致力于将全球创新智慧深度融入中国本土实践的一个典型范例。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4817516_ZH17516_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4588","IE0002141913.USD","IE0009355771.USD","IE00B2B36J28.USD","NVS","BK4007","LU0320765489.SGD","SIEGY","IE00BJT1NW94.SGD","SMMNY","BK4082","IE00B4R5TH58.HKD","BK4585","BK4543","LU0211331839.USD","BK4532","IE00BJJMRZ35.SGD","BK4578","LU0070302665.USD","BK4206","LU0208291251.USD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2581691098","title":"由于生产成本降低和研发削减，莫德纳 下调了年度支出展望","url":"https://stock-news.laohu8.com/highlight/detail?id=2581691098","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581691098?lang=zh_cn&edition=fundamental","pubTime":"2025-11-06 20:48","pubTimestamp":1762433309,"startTime":"0","endTime":"0","summary":"更新版 2-由于生产成本降低和研发削减，莫德纳 下调了年度支出展望改写第 1 段，提及支出前景，在第 3、4 段中增加首席财务官的引语莫德纳 将年度运营支出减少 7 亿美元美国指南限制 新冠 注射，影响疫苗接种率莫德纳 第三季度收入超出预期，但 COVID 疫苗销售额下降Patrick Wingrove/Christy Santhosh. 莫德纳公司将2025年的调整后营业支出预期下调了7亿美元，至52亿至54亿美元之间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL4S3WI1CH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0225771236.USD","BK4578","LU2087621335.USD","BK4599","LU0109394709.USD","SG9999002224.SGD","LU1674673428.USD","SG9999003800.SGD","BK4534","SG9999013999.USD","IE00B7SZLL34.SGD","LU0456855351.SGD","LU1674673691.USD","LU0225284248.USD","LU1778281490.HKD","IE0002270589.USD","BK4501","IE00BZ1G4Q59.USD","IE00BLSP4452.SGD","GILD","SG9999002232.USD","SG9999001176.SGD","BK4588","LU1023059063.AUD","LU0321505439.SGD","SG9999011175.SGD","LU0882574055.USD","SG9999015978.USD","LU1430594728.SGD","MRNA","IE00BSNM7G36.USD","LU0320765992.SGD","BK4551","LU0122379950.USD","BK4585","LU0234570918.USD","LU0985481810.HKD","LU1585245621.USD","LU1894683264.USD","IE00B19Z3581.USD","IE00BBT3K403.USD","BK4581","BK4550","LU0889565916.HKD","LU1839511570.USD","SG9999015986.USD","IE00B19Z3B42.SGD","LU2324357040.USD"],"gpt_icon":1},{"id":"2581064775","title":"由于 COVID 疫苗销售疲软，莫德纳 下调了全年预期上限","url":"https://stock-news.laohu8.com/highlight/detail?id=2581064775","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581064775?lang=zh_cn&edition=fundamental","pubTime":"2025-11-06 20:00","pubTimestamp":1762430404,"startTime":"0","endTime":"0","summary":"由于 COVID 疫苗销售疲软，莫德纳 下调了全年预期上限莫德纳 第三季度收入同比下降 45新冠 疫苗的销售额为 9.71 亿美元，高于降低的预期首席财务官称疾控中心迟来的指导意见损害了 COVID 疫苗的销售额Patrick Wingrove. 路透11月6日 - 莫德纳 MRNA.O周四将其2025年收入预期的上限下调了2亿美元，理由是由于美国人难以获得新冠疫苗，该疫苗在美国的销售额低于预期。8 月，美国食品和药物管理局限制老年人和高危人群接种更新的 COVID 疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL4T3WI153:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015978.USD","BK4501","BK4585","LU0289739699.SGD","BK4550","LU1430594728.SGD","LU2087621335.USD","IE00BZ1G4Q59.USD","MRNA","LU0882574055.USD","LU2324357040.USD","LU1674673691.USD","LU0225771236.USD","BK4534","LU1057294990.SGD","SG9999013999.USD","LU0985481810.HKD","LU0122379950.USD","LU1023059063.AUD","LU0889565916.HKD","BK4007","IE00B19Z3581.USD","BK4533","IE00B7SZLL34.SGD","LU0109394709.USD","SG9999001176.USD","SG9999015945.SGD","LU0170899867.USD","BK4583","LU0456855351.SGD","BK4578","LU2089984988.USD","LU0321505439.SGD","LU1674673428.USD","BK4568","LU0114720955.EUR","LU0058720904.USD","LU0234572021.USD","LU0320765992.SGD","GILD","LU1894683348.USD","SG9999015952.SGD","IE00BBT3K403.USD","BK4599","LU1066053197.SGD","IE00B3T34201.USD","IE000M9KFDE8.USD","BK4566","BK4588"],"gpt_icon":1},{"id":"2581054016","title":"诺华制药(NVS.US)首个放射配体疗法药物派威妥®双适应症同时获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2581054016","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581054016?lang=zh_cn&edition=fundamental","pubTime":"2025-11-06 16:51","pubTimestamp":1762419078,"startTime":"0","endTime":"0","summary":"作为国内首个且目前唯一获批的靶向PSMA的放射配体疗法药物，派威妥的这两个适应症此前均获得优先审评认定，此次同时获批，有望为更多治疗选择有限的中国晚期前列腺癌患者，提供延长生存并改善生活质量的全新治疗方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366060.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0208291251.USD","BK4578","IE00BJJMRZ35.SGD","01477","IE0002141913.USD","BK4588","IE00BJT1NW94.SGD","BK1574","BK4585","NVS","IE00B4R5TH58.HKD","LU0211331839.USD","LU0070302665.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU0320765489.SGD","BK4007","BK1191","IE0009355771.USD","BK4532"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":30,"code":"91000000","status":"200"}]}}